We have recently closed an investment in Brainomix for the Parkwalk Opportunities EIS Fund and the University of Oxford Innovation Fund IV.
Brainomix, the medical imaging company using artificial intelligence (AI) for the fast diagnosis and treatment of stroke victims, has closed a £7m ($9.8m) funding roundt to bring its software to the global healthcare market.
Parkwalk lead the round and was joined by Boehringer Ingelheim Venture Fund (BIVF), the corporate venture fund of the global pharmaceutical company Boehringer Ingelheim, a driving force in the field of stroke. Existing investors Chimera Partners and the Parkwalk-managed Oxford University Innovation Fund also participated.
Brainomix’s flagship software solution, e-ASPECTS, uses AI to provide a fast and standardised assessment of stroke patient CT scans, supporting quick and consistent treatment decisions by medical professionals, irrespective of their experience and expertise. The software works by automating the clinically-validated Alberta Stroke Program Early CT Score (ASPECTS) method. e-ASPECTS provides physicians with a clinical support tool that is designed to improve stroke treatment outcomes at much lower overall cost.
The injection of cash will allow Brainomix to further commercialise its intelligent medical imaging and workflow software solutions and expand its market penetration around the world.
The company’s website can be viewed here.
